Zigguratum, Inc.

Zigguratum, Inc., a small business based in Chattanooga, Tennessee, competes as a prime contractor on federal research and development awards under total small business set-asides, with three recent contracts totaling $5.9 million across the National Institutes of Health (including ARPA-H) and the Defense Advanced Research Projects Agency. The vendor operates entirely as a prime — zero subcontract activity to date — and self-performs all technical work.

Zigguratum's award footprint is concentrated in biomedical and defense security research. The National Institutes of Health accounts for two awards and $4.1 million in combined potential value, anchored by a $3.5 million SBIR Phase II definitive contract awarded August 1, 2026, for research and development within the ESCAPE program (Enhancing Security Capabilities Through an Analytic Platform Ecosystem), running through January 31, 2028, under NAICS 541715 (Research and Development in the Physical, Engineering, and Life Sciences). The earlier Phase I award from NIH/ARPA-H — a $594,676 definitive contract for the same ESCAPE topic, completed June 12, 2025 — delivered a feasibility study on security capabilities and analytics platforms with performance in Spokane, Washington. DARPA's $1.757 million award (September 12, 2025, completed November 10, 2026) also addressed ESCAPE under total small business set-aside. All three contracts carry firm fixed price structures.

The vendor's SCI-reported service-contract activity shows modest but growing invoiced revenue: $238 thousand in FY2024 (1.3 FTEs, roughly 2,612 contractor hours derived to $91.07/hr) and $476 thousand in FY2025 (1.7 FTEs). SCI covers federal service contracts above the $150,000 reporting threshold and excludes goods, products, micro-purchases, and classified work; these figures represent a strict subset of federal services revenue and do not reflect total enterprise revenue. Zigguratum self-performed 100% of reported hours across both SCI-reportable prime contracts with no named subcontractors.

Two awards face recompete or completion within the next twenty-four months: the Phase I award (already completed June 2025) and the DARPA ESCAPE contract (completing November 2026), representing $5.3 million in combined potential value. The Phase II award runs through January 2028 and represents the vendor's longest-duration commitment. Zigguratum's entire visible federal footprint centers on ESCAPE-related research, signaling deep specialization in security analytics and platform ecosystems across health and defense customer sets.